ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting

    Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis

    Tatjana Mallano1, Katrin Palumbo-Zerr1, Christian Beyer1, Clara Dees1, Jingang Huang1, Tsonwin Hai2, Georg A. Schett3 and Joerg H. W. Distler1, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2The Ohio State Biochemistry Program, The Ohio State University, Columbus, USA, Colombus, OH, 3Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

    Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…
  • Abstract Number: 826 • 2013 ACR/ARHP Annual Meeting

    The Value Of History and Physical Examination Findings In The Diagnosis Of Symptomatic Meniscal Tear Among Middle-Age Subjects With Knee Pain

    Jeffrey N. Katz1, Yan Dong2, John Wright3, Stephanie Chen4, Scott Martin5, Laurel Donnell-Fink5, Benjamin N. Rome2 and Elena Losina2, 1Rheumatology and Orthopedics, Brigham and Women's Hospital, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 3Orthopedic Surgery, Brigham and Women's Hospital, Boston, MA, 4Orthopedics and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, 5Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Clinicians often rely on mechanical symptoms (e.g. clicking, catching, popping, giving way) and tests such as the McMurray sign in the diagnosis of symptomatic…
  • Abstract Number: 827 • 2013 ACR/ARHP Annual Meeting

    Cost-Effectiveness and Cost-Utility Of a One-Year Coaching Program For Healthy Physical Activity In Rheumatoid Arthritis

    Nina Brodin1,2, Malin Lohela Karlsson3, Emma Swärdh2 and Christina H. Opava4, 1Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, 2Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, SE 14183 Huddinge, Sweden, 3Institute of Environmental Medicine (IMM), Intervention and Implementation Research Unit, Karolinska Institutet, Stockholm, Sweden, 4Neurobiology, Care Sciences and Society, Division of Physical Therapy, Karolinska Institutet, Huddinge, Sweden

    Background/Purpose: Economic evaluations of interventions, as a complement to the effect evaluation, intend to inform decision makers about whether an intervention provides good value for…
  • Abstract Number: 788 • 2013 ACR/ARHP Annual Meeting

    Efficacy Of Tocilizumab In Refractory Adult-Onset Still’s Disease: Multicenter Study Of 32 Patients

    Francisco Ortiz-Sanjuan1, Ricardo Blanco2, Javier Narvaez3, Esteban Rubio Romero4, Alejandro Olivé5, Santos Castañeda6, Adela Gallego Flores7, M. Victoria Hernández8, Cristina Mata1, Inmaculada Ros Vilamajo9, Alberto Sifuentes Giraldo10, M Caracuel11, Mercedes Freire12, Catalina Gómez Arango13, José Llobet14, Sara Manrique Arija15, Carlos Marras16, Concepcion Moll Tuduri17, Chamaida Plasencia Rodriguez18, Rosa Roselló19, Ana Urruticoechea20, Maria Luisa Velloso Feijoo21, Javier Loricera1, Vanesa Calvo-Rio1 and Miguel A González-Gay22, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV. Santander. Spain, Santander, Spain, 2Hospital Marques de Valdecilla, Santander, Spain, 3Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 4Rheumatology, Hospital Universitario Virgen del Rocío. Sevilla. Spain, Sevilla, Spain, 5Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 6Rheumatology, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain, 7Rheumatology, Hospital de Mérida, Mérida, Spain, 8Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, 9Hospital Son Llàtzer, Palma de Mallorca, Spain, 10Rheumatology, H Ramón y Cajal, Madrid, Spain, 11Rheumatology., Hospital de Córdoba., Córdoba, Spain, 12Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, 13HU Basurto, Bilbao, Spain, 14H Sant Pau, Barcelona, Spain, 15HRU Carlos Haya, Málaga, Spain, 16Rheumatology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain, 17Hospital Mateu Orfila. Menorca. Spain, Mahón (Menorca), Spain, 18HU La Paz, Madrid, Spain, 19H San Jorge, Huesca, Spain, 20Hospital Can Misses, Ibiza, Spain, 21H Valme, Sevilla, Spain, 22Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain

    Background/Purpose: Adult-onset Still's disease (AOSD) is frequently refractory to standard immunosuppressive drugs and it may require biological therapy. Tocilizumab (TCZ) has demonstrated efficacy in clinical…
  • Abstract Number: 789 • 2013 ACR/ARHP Annual Meeting

    Sirolimus Plus Prednisone For Erdheim-Chester Disease: A Pilot Trial

    Davide Gianfreda1, Federico Alberici2, Maricla Galetti3, Maria Nicastro3, Carlo Buzio4 and Augusto Vaglio5, 1University of Parma, Parma, Italy, 2Department of Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, 3Nephrology University of Parma, Parma, Italy, 4Clinical Medicine, Nephrology and Health Sciences, University of Parma, Parma, Italy, 5Unit of Nephrology, University Hospital of Parma, Parma, Italy

    Background/Purpose: Erdheim-Chester disease (ECD) is an extremely rare form of non-Langerhans cell histiocytosis. The pathogenesis of ECD is unclear: while most authors suggest the hypothesis…
  • Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting

    Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course

    Carol A. Wallace1, Edward H. Giannini2, Steven J. Spalding3, Philip J. Hashkes4, Kathleen M. O'Neil5, Andrew S. Zeft6, Ilona S. Szer7, Sarah Ringold8, Hermine Brunner9, Laura E. Schanberg10, Robert P. Sundel11, Diana Milojevic12, Marilynn G. Punaro13, Peter Chira14, Beth S. Gottlieb15, Gloria C. Higgins16, Norman T. Ilowite17, Yukiko Kimura18, Anne Johnson9, Bin Huang19 and Daniel J. Lovell2, 1University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, 2Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 3Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, 4Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, 5Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, 6Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, 7Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, 8Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, 9Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 10Pediatrics, Duke University Medical Center, Durham, NC, 11Division of Immunology, Boston Children's Hospital, Boston, MA, 12Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, 13Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, 14Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, 15Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, 16Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, 17Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, 18Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, 19Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH

    Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
  • Abstract Number: 791 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety Of Tocilizumab In Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: 2-Year Data From Cherish

    Hermine I. Brunner1, Nicolino Ruperto2, Zbigniew Zuber2, Rubén J. Cuttica3, Ricardo Xavier2, Inmaculada Calvo2, Nadina Rubio2, Ekaterina Alekseeva2, Vyacheslav Chasnyk4, Jose Chavez2, Gerd Horneff2, Violetta Opoka-Winiarska2, Pierre Quartier5, Alberto Spindler6, Caroline Keane7, Kamal N. Bharucha8, Jianmei Wang9, Daniel J. Lovell1, Alberto Martini2 and Fabrizio De Benedetti10, 1PRCSG, Cincinnati, OH, 2PRINTO, Genoa, Italy, 3Hospital de Niños Pedro de Elizalde - University of Buenos Aires, Buenes Aires, Argentina, 4Hospital Pediatry, State Pediatric Medical University, Saint-Petersburg, Russia, 5Pediatria II, Istituto Giannina Gaslini, Genoa, Italy, 6PRINTO, Genoa, OH, Italy, 7Roche, Welwyn Garden City, United Kingdom, 8Genentech, South San Francisco, CA, 9Roche Products Ltd., Welwyn Garden City, United Kingdom, 10Division of Rheumatology, Department of Pediatric Medicine, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

    Background/Purpose: Efficacy and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, were previously demonstrated at week 40 of CHERISH, a phase 3 trial in patients…
  • Abstract Number: 792 • 2013 ACR/ARHP Annual Meeting

    Methotrexate Polyglutamates in Erythrocytes Are Associated With Lower Disease Activity in Juvenile Idiopathic Arthritis Patients

    Maja Bulatovic Calasan1, Ethan den Boer2, Maurits C.F.J. De Rotte3, S.J. Vastert4, Sylvia Kamphuis5, Robert De Jonge3 and Nico M. Wulffraat6, 1Paediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 2Clinical Chemistry, Erasmus MC University Medical Center, Rotterdam, Netherlands, 3Clinical Chemistry, Erasmus Medical Center, Rotterdam, Netherlands, 4Pediatric Rheumatology, University Medical Center Utrecht, Utrecht, Netherlands, 5Pediatric Rheumatology, Eramus MC Sophia Children's Hospital, Rotterdam, Netherlands, 6Pediatric Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose:  Methotrexate polyglutamates (MTX-PG) could be biomarkers of MTX response and adverse effects and could thus be used as a therapeutic drug monitoring (TDM) tool to steer tailor-made therapeutic…
  • Abstract Number: 793 • 2013 ACR/ARHP Annual Meeting

    Efficacy and Safety of Adalimumab in Pediatric Patients With Enthesitis Related Arthritis

    Rubén Burgos-Vargas1, Shirley M.L. Tse2, Gerd Horneff3, Aileen L. Pangan4, Kristina Unnebrink5 and Jaclyn K. Anderson4, 1Rheumatology, Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 2Pediatric Rheumatology, University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4AbbVie Inc., North Chicago, IL, 5AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany

    Background/Purpose: Enthesitis related arthritis (ERA) is a subcategory of juvenile idiopathic arthritis (JIA) which primarily affects peripheral joints and entheses but also can involve the…
  • Abstract Number: 794 • 2013 ACR/ARHP Annual Meeting

    Recent Trends In Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of TNF Inhibitors

    Melissa L. Mannion1, Fenglong Xie2, Jeffrey R. Curtis3 and Timothy Beukelman1, 1Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The pharmacologic management of JIA has changed dramatically with the advent of tumor necrosis factor inhibitors (TNFi), but the impact of TNFi on medication…
  • Abstract Number: 795 • 2013 ACR/ARHP Annual Meeting

    Second TNF-Inhibitor Or Alternative Biologic In Juvenile Idiopathic Arthritis (JIA) Patients Failing a First TNF-Inhibitor

    Kirsten Minden1, Klaus Tenbrock2, Gerd Horneff3 and Hans-Iko Huppertz4, 1Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, 2University Aachen, Aachen, Germany, 3Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 4Prof. Hess Childrens Hospital, Bremen, Germany

    Background/Purpose: Patients with incomplete response to initial anti-TNF treatment often are switched to other biologic treatments. However, little is known about the efficacy of switching…
  • Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting

    Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)

    Michael H. Schiff1, Lee S. Simon2, Bruce Freundlich3, Jonathan Jaffe4 and Kaushik J. Dave5, 1Rheumatology Division, University of Colorado, Denver, CO, 2SDG LLC Consulting, West Newton, MA, 3University of Pennsylvania, Philadelphia, PA, 4Clinical Development, Antares Pharma Inc, Ewing, NJ, 5Product Development, Antares Pharma Inc, Ewing, NJ

    Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…
  • Abstract Number: 797 • 2013 ACR/ARHP Annual Meeting

    Methotrexate Exposure Assessment In Routine Clinical Rheumatology Practice: Effect Of Dosing and Route Of Administration On Polyglutamate Levels

    Roy A. Kaplan1, Brigid Freyne2, Derren Barken3 and Thierry Dervieux4, 1Private Practice / Scripps Health, Encinitas, CA, 2Private Practice, Murietta, CA, 3Exagen Diagnostics, Vista, CA, 4Research and Development, Exagen Diagnostics, Vista, CA

    Background/Purpose: Large interpatient variability in Methotrexate (MTX) absorption and intracellular activation to methotrexate polyglutamates (MTXPGs) can explain, in part, the large spectrum of MTX response…
  • Abstract Number: 798 • 2013 ACR/ARHP Annual Meeting

    Targeting Ultrasound Remission In Early Rheumatoid Arthritis – Results Of The Taser Study

    James Dale1, Anne Stirling2, Iain B. McInnes1 and Duncan Porter3, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, 2Gartnavel General Hospital, Glasgow, United Kingdom, 3Rheumatology, Gartnavel General Hospital, Glasgow, United Kingdom

    Background/Purpose: The TaSER study (NCT00920478) is an open label randomized clinical trial with blinded assessments of outcome. It was designed to test whether the efficacy…
  • Abstract Number: 799 • 2013 ACR/ARHP Annual Meeting

    Clinical and Radiological Outcomes Of Two Years Remission Steered Treatment In Early Arthritis Patients

    L. Heimans1, K.V.C. Wevers-de Boer1, G. Akdemir1, H.K Ronday2, T.H.E. Molenaar3, J. H. L. M. Van Groenendael4, A.J. Peeters5, I. Speyer6, G. Collee7, P.B. de Sonnaville8, B.A. Grillet9, T.W.J. Huizinga1 and C.F. Allaart1, 1Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Haga Hospital, The Hague, Netherlands, 3Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, 4Franciscus Hospital, Roosendaal, Netherlands, 5Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, 6Rheumatology, Bronovo Hospital, Den Haag, Netherlands, 7MCH, The Hague, Netherlands, 8Department of Rheumatology, Admiraal de Ruyter hospital, Goes, Netherlands, 9Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands

    Background/Purpose: To evaluate outcomes after 2 years of remission steered therapy in early arthritis patients. Methods: 610 patients with early rheumatoid or undifferentiated arthritis (UA)…
  • « Previous Page
  • 1
  • …
  • 2194
  • 2195
  • 2196
  • 2197
  • 2198
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology